S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Ligand Reports Third Quarter 2014 Financial Results|
|Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan|
|Ligand Provides Highlights from Today’s Analyst Day Event|
|Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for Captisol-Enabled™ Melphalan|
|Ligand Partner Pfizer Receives European Marketing Authorization for DUAVIVE® (Conjugated Estrogens/Bazedoxifene) for Treatment of Estrogen Deficiency Symptoms in Postmenopausal Women with a Uterus|
|Ligand Partner Melinta Therapeutics Reports Positive Phase 3 Results for Captisol-enabled™ Delafloxacin IV|
|Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia Indication for Revolade™ (eltrombopag)|
|Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for Promacta®|
|Spectrum Pharmaceuticals Files a New Drug Application with the FDA for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan|
|UPDATE: Strong bull trend reaches uncharted -2- (2014/11/25)|
Click above to view more mutual fund data and stats for lgnd - Ligand Pharmaceuticals Inc.